Prosecution Insights
Last updated: April 19, 2026
Application No. 18/451,523

SOFT TISSUE MARKER FOR ATTACHMENT TO A SURGICAL EXCISION BED AND METHOD OF MARKING SURGICAL SITE

Final Rejection §102§103
Filed
Aug 17, 2023
Examiner
MALAMUD, DEBORAH LESLIE
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Merit Medical Systems Inc.
OA Round
2 (Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
3y 5m
To Grant
89%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
666 granted / 847 resolved
+8.6% vs TC avg
Moderate +10% lift
Without
With
+10.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
44 currently pending
Career history
891
Total Applications
across all art units

Statute-Specific Performance

§101
10.7%
-29.3% vs TC avg
§103
27.0%
-13.0% vs TC avg
§102
43.5%
+3.5% vs TC avg
§112
15.4%
-24.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 847 resolved cases

Office Action

§102 §103
DETAILED ACTION The Examiner acknowledges the amendments received 27 January 2026. Claims 15-20 are withdrawn; claims 1-14 are pending. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, see “Remarks”, filed 27 January 2026, with respect to the rejection(s) of claim(s) 1-14 under Corbitt and Wallace have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Purcell. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2, 4-5 and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Purcell et al (U.S. 2019/0216601). Purcell discloses (Figures 2A-2B) an elongate element (suture 74); a needle (sharpened distal end 64) disposed at a distal end of the elongate element; and at least one radiopaque marker element (66) comprising a coil (par. 055) coupled to or disposed on at least a portion of an outer surface of the elongate element (“A coil spring 71 is concentrically carried over the core wire 62 and biases the radiopaque marker 66 in the distal direction. The radiopaque marker 66 is thus held in position against a proximal surface of the stop 70. In use, the marker 66 rides on the surface of tissue at the target attachment site. As the helical coil anchor 54 is rotated and advances distally into tissue, the marker 66 rides proximally on the core wire 62 along with the tissue surface, compressing the coil spring 71 until the marker 66 is retracted proximally to the hub when the tissue anchor is fully embedded.”). Regarding claim 2, Purcell discloses (Figures 2A-2B) the elongate element is suture (74). Regarding claim 4, Purcell discloses (par. 0055) the at least one radiopaque marker element includes a helical coil (“A coil spring 71 is concentrically carried over the core wire 62 and biases the radiopaque marker 66 in the distal direction. The radiopaque marker 66 is thus held in position against a proximal surface of the stop 70. In use, the marker 66 rides on the surface of tissue at the target attachment site. As the helical coil anchor 54 is rotated and advances distally into tissue, the marker 66 rides proximally on the core wire 62 along with the tissue surface, compressing the coil spring 71 until the marker 66 is retracted proximally to the hub when the tissue anchor is fully embedded.”). Regarding claim 5, Purcell discloses (par. 0055) the helical coil is wrapped around the elongate element (“A coil spring 71 is concentrically carried over the core wire 62 and biases the radiopaque marker 66 in the distal direction. The radiopaque marker 66 is thus held in position against a proximal surface of the stop 70. In use, the marker 66 rides on the surface of tissue at the target attachment site. As the helical coil anchor 54 is rotated and advances distally into tissue, the marker 66 rides proximally on the core wire 62 along with the tissue surface, compressing the coil spring 71 until the marker 66 is retracted proximally to the hub when the tissue anchor is fully embedded.”). Regarding claim 14, Purcell discloses (par. 0056) the at least one radiopaque marker element includes a plurality of connected radiopaque marker elements (“The suture may additionally carry one or two or more radiopaque markers 82 spaced apart from the hub 57, and may extend proximally through the proximal connector and a central lumen in the rotational driver.”). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 3 and 6-13 are rejected under 35 U.S.C. 103 as being unpatentable over Purcell et al (U.S. 2019/0216601) in view of Wallace et al (U.S. 7,695,484). Purcell discloses the claimed invention except for the at least one radiopaque marker includes portions having different radiopacities. Wallace, however, discloses (col. 6, lines 4-59) a helically coiled radiopaque device that varies its pitch from open to closed along its length in order to provide variable thickness and density. Wallace and Purcell both disclose systems for providing helically coiled radiopaque elements in an implanted device. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify Purcell’s needle system with Wallace’s varying winding along the length of the elongate element in order to provide variable shape and flexibility for stability in placement of the device. Regarding claim 6, Wallace discloses (col. 6, lines 4-59) the helical coil includes portions having different winding densities, and wherein the different winding densities have different radiopacities. Regarding claim 7, Wallace discloses (col. 6, lines 4-59) the helical coil includes a plurality of high-density winding portions that are spaced apart along at least a portion of the elongate element. Regarding claim 8, Wallace discloses (col. 6, lines 4-59) the plurality of high-density winding portions are unconnected. Regarding claim 9, Wallace discloses (col. 6, lines 4-59) the helical coil includes a plurality of high-density winding portions that are separated by low-density winding portions along at least a portion of the elongate element. Regarding claim 10, Wallace discloses (col. 6, lines 4-59) the plurality of high-density winding portions comprise different radiopacities. Regarding claim 11, Wallace discloses (col. 6, lines 4-59) the high-density winding portions and the low-density winding portion create a pattern of radiopacity. Regarding claim 12, Wallace discloses (col. 6, lines 4-59) the pattern of radiopacity repeats along the elongate element. Regarding claim 13, Wallace discloses (col. 6, lines 4-59) the at least one radiopaque marker element is configured for varying tactile and visual feedback via modifications of a coil density of the helical coil. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBORAH L MALAMUD whose telephone number is (571)272-2106. The examiner can normally be reached Mon - Fri 1:00-9:30 Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Unsu Jung can be reached at (571) 272-8506. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEBORAH L MALAMUD/Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Aug 17, 2023
Application Filed
Oct 23, 2025
Non-Final Rejection — §102, §103
Jan 27, 2026
Response Filed
Feb 10, 2026
Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12598433
VAGAL NERVE STIMULATION DEVICES AND METHODS
2y 5m to grant Granted Apr 07, 2026
Patent 12594418
DEVICES AND METHODS FOR NERVE STIMULATION
2y 5m to grant Granted Apr 07, 2026
Patent 12588868
BIPOLAR MAPPING SUCTION DEVICE
2y 5m to grant Granted Mar 31, 2026
Patent 12586687
SYSTEMS AND METHODS OF DEDUPLICATING DATA COLLECTED BY AN IMPLANTABLE MEDICAL DEVICE
2y 5m to grant Granted Mar 24, 2026
Patent 12575795
NON-INVASIVE PREDICTION OF RISK FOR SUDDEN CARDIAC DEATH
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
89%
With Interview (+10.0%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 847 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month